International Team Renames PCOS to PMOS for 170 Million Women After 10-Year Push
Updated
Updated · The Conversation · May 29
International Team Renames PCOS to PMOS for 170 Million Women After 10-Year Push
7 articles · Updated · The Conversation · May 29
The Lancet study published May 12 formally recasts polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome, aiming to reflect a disorder that spans hormones, metabolism, mental health, skin and reproduction.
About 1 in 8 women globally—more than 170 million—are affected, yet an estimated 70% remain undiagnosed, partly because the old name wrongly centered ovarian cysts and often delayed diagnosis by more than a year.
A 2025 U.S. study of 87,000 women found over 45% of those with PMOS had metabolic disease, versus about 25% without it; more than 16% had fertility problems, compared with under 4% of peers.
The renaming followed a 10-year process with more than 14,000 participants, and 86% of patients surveyed backed a change after a 2015 global push from patients and clinicians.
The team plans a three-year transition to PMOS worldwide, with the new term set for the 2028 international guideline in hopes of improving screening, earlier treatment and coordinated care.
Now that PMOS is a systemic disorder, could men be diagnosed and what would their symptoms be?
With PMOS now defined as a metabolic disease, should screening become a routine part of adolescent health checks?
Beyond a new name, what concrete changes in diagnostic testing will actually speed up patient care?
From PCOS to PMOS: The 2026 Global Redefinition Transforming Diagnosis, Treatment, and Stigma
Overview
In May 2026, Polycystic Ovary Syndrome (PCOS) was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect its complex and systemic nature. The old name focused too much on ovarian cysts, which led to misunderstandings and made many think it was only a reproductive issue. This narrow view often hid the broader health risks, like diabetes and heart disease, and made it harder for patients to get a proper diagnosis and care. The new name aims to improve scientific accuracy, reduce stigma, and support more holistic treatment for millions affected by this condition.